Long Term Analytical Validation Study Further Confirms BluePrint as a Reliable Genomic Profiling Assay for Early Stage Breast Cancer Patients
PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – [Read More]
Agendia COVID-19 Statement
As a valued customer we wanted to reach out and [Read More]
Miami Breast 2020 FLEX Trials in Progress
AUTHORS: Robert Maganini, Pond Kelemen, Jennifer A. Crozier, Gordan Srkalovic, [Read More]
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
PUBLICATION: Soliman et al. BMC Cancer (2020) 20:81 AUTHORS: Hatem [Read More]
Results from the IMPACt Trial Show Agendia Assays Consistently Inform Treatment Planning and Increase Physician Confidence when Caring for Patients with Early Stage Breast Cancer
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, [Read More]
Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award at Precision Medicine World Conference 2020
PRESS RELEASE Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, [Read More]
Breast Cancer Patients in Germany Now have Insurance Coverage for MammaPrint® Testing through Techniker Krankenkasse
PRESS RELEASE Breast Cancer Patients in Germany Now have Insurance [Read More]
PROMIS study findings presented at SABCS 2019
PRESS RELEASE New Data Compare Genomic Profiling Results for Premenopausal [Read More]
SABCS 2019: Cyclin E Expression
AUTHORS: Lorenza Mittempergher, Joseph McKelley, Rajith Bhaskaran, Sahra Uygun, René [Read More]
SABCS 2019: FLEX Trials in Progress
AUTHORS: Jennifer Crozier, Gordan Srkalovic, Adam Brufsky, Mehran Habibi, Pat [Read More]